Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/9/2018
SIETES contiene 92559 citas

 
 
 1 a 20 de 157 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Watanabe JH, McInnis T, Hirsch JD. Cost of prescription drug-related morbidity and mortality.. Annals of Pharmacotherapy 2018;52:829-37. [Ref.ID 102573]
2.Enlace a cita original Cita con resumen
Avorn J. The psychology of clinical decision making — Implications for medication use. N Engl J Med 2018;378:22 de febrero. [Ref.ID 102556]
3. Cita con resumen
Rawshani A, Svensson A-M, Zethelius B, Eliasson B, Rosengren A, Gudbjömsdottir S. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern Med 2016;176:1146-54. [Ref.ID 100702]
5.Tiene citas relacionadas Cita con resumen
Meier F, Maas R, Sonst A, Patapovas A, Müller F, Plank-Kiegele B, Pfistermeister B, Schöffski O, Bürkle T, Dormann H. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol Drug Saf 2015;24:176-86. [Ref.ID 99600]
6. Cita con resumen
Allen K, Pearson-Stuttard J, Hooton W, Diggle P, Capewell S, O’Flaherty M. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. BMJ 2015;351:h4583. [Ref.ID 99541]
7. Cita con resumen
Gellad WF, Donohue JM, Zhao X, Mor MK, Thorpe CT, Smith J, Good CB, Fine MJ, Morden NE. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison. Ann Intern Med 2013;159:105-14. [Ref.ID 95864]
8. Cita con resumen
Rawlins M. NICE times: a valedictory dispatch. Lancet 2013;381:2225-7. [Ref.ID 95752]
9. Cita con resumen
Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantolff PW, Lee PA, McMahon PM. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med 2013;158:853-60. [Ref.ID 95679]
10. Cita con resumen
Chinthapalli K. NICE is dead; long live NICE. BMJ 2013;346:16. [Ref.ID 95480]
11. Cita con resumen
Spence D. Beware the cost-benefit analysis. BMJ 2012;345:47. [Ref.ID 93508]
12. Cita con resumen
Bilinski K, Boyage S. The rise and rise of vitamin D testing. BMJ 2012;345:e4743. [Ref.ID 93445]
13.Tiene citas relacionadas Cita con resumen
Yudkin JS. Catastrophic health expenditure. BMJ 2012;344:29. [Ref.ID 93250]
15. Cita con resumen
Vallano Ferraz A, Agustí Escassany A, Pedrós Cholvi C, Arnau de Bolós JM. Revisión sistemática de los estudios de evaluación del coste de las reacciones adversas a medicamentos. Gaceta Sanitaria 2012;26:277-83. [Ref.ID 91994]
16. Cita con resumen
Fuchs VR. The doctor's dilemma — What Is “appropriate” care?. N Engl J Med 2011;365:585-7. [Ref.ID 91006]
17. Cita con resumen
Spink MJ, Menz HB, Fotoohabadi MR, Wee E, Landorf KB, Hill KD, Lord SR. Effectiveness of a multifaceted podiatry intervention to prevent falls in community dwelling older people with disabling foot pain: randomised controlled trial. BMJ 2011;342:d3411. [Ref.ID 90814]
18. Cita con resumen
Anónimo. NICE has approved 73% of cancer drugs since 2002. BMJ 2010;341:798. [Ref.ID 89509]
19.Tiene citas relacionadas Cita con resumen
McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N, Abrams K. Continuing the scheme is unjustified. BMJ 2010;340:1285,1287-1288. [Ref.ID 88681]
20.Tiene citas relacionadas Cita con resumen
Raftery J. Costly failure of a risk sharing scheme. BMJ 2010;340:1282-4. [Ref.ID 88680]
Seleccionar todas
 
 1 a 20 de 157 siguiente >>